SCHEMBL7085446

SCHEMBL7085446

Cc1cc(Cl)cc(C(=O)C(=O)c2cccc(-c3ccc(F)cc3)c2-c2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
ACLY P53396 4/20 0.38
KDR P35968 1/20 0.37
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SHMT1 P34896 1/20 0.37
MAPT P10636 2/20 0.36
FABP3 P05413 1/20 0.36
FABP4 P15090 1/20 0.36
HNF4A P41235 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
TP53 P04637 1/20 0.34
HAO2 Q9NYQ3 1/20 0.34
PPARG P37231 1/20 0.34
POLB P06746 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7083942 0.86 PTGS2 (0.46)
SCHEMBL7090744 0.81 SLC6A4 (0.41) SLC6A4SLC6A3HTTL3MBTL1MAPT
SCHEMBL7090146 0.80 SLC6A4 (0.39) SLC6A4SLC6A3ACLYHTTL3MBTL1
SCHEMBL7088117 0.78 ALDH1A1 (0.52) SLC6A4SLC6A3ACLYHTTMAPT
SCHEMBL7089297 0.78 PTGS2 (0.50)
SCHEMBL7085442 0.74 SLC6A4 (0.39) SLC6A4SLC6A3SHMT1MAPTSMN1; SMN2
SCHEMBL3806469 0.74 HNF4A (0.53) L3MBTL1MAPTFABP3FABP4HNF4A
SCHEMBL7090554 0.72 NPSR1 (0.37) HTTL3MBTL1MAPTFABP4HNF4A
SCHEMBL30370009 0.71 BCAT2 (0.57) SLC6A4SLC6A3HTTMAPTHNF4A
SCHEMBL9864618 0.70 MAPT (0.40) MAPTHNF4AHPGDNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 SLC6A4 2737/4885SLC6A3 3343/4885ACLY 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.